Drug Trial Radar · NCT04669067
TL-895 and KRT-232 Study in Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Feb 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
18
Actual
Start
Mar 31, 2021
Primary completion
Nov 2024
Study completion Nov 2025
Sponsor
- Lead sponsor
- Telios Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Kartos Therapeutics, Inc.
- First posted
- Dec 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.
Conditions
- Acute Myeloid Leukemia
Interventions
TL-895Drug
TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
KRT-232Drug
KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Objective, Phase 1b: To determine the MTD/MAD and recommended Phase 2 dose (RP2D) of TL-895 in combination with KRT-232Time frame: 13 months
- Primary Objective, Phase 2: To determine the rates of complete remission (CR) and complete remission with partial hematologic recovery (CRh)Time frame: 41 months
Locations
35 sites in 8 countries. Site status is shown where the registry gives one.
Keck School of Medicine
Los Angeles, California
University of California, Irvine Medical Center
Orange, California
Georgia Cancer Center
Augusta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
Rush University Medical Center, Division of Hematology Oncology and Cell Therapy
Chicago, Illinois
Karmanos Cancer Institute
Detroit, Michigan
Weill Cornell Medical College
New York, New York
University of Cincinnati
Cincinnati, Ohio
Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization
Philadelphia, Pennsylvania
UT Southwestern Medical Center, Harold C. Simmons Cancer Center
Dallas, Texas
Seattle Cancer Care Alliance
Seattle, Washington
University of Sunshine Coast-Sippy Downs
Sippy Downs, Australia
Westmead Hospital
Sydney, Australia
Ordensklinikum Linz GmbH Elisabethinen
Linz, Austria
Medical University Vienna, Department of Internal Medicine I, Clinical Department of Hematology and Hemostaseology
Vienna, Austria
Claude Huriez Hospital
Lille, France
South Lyon Hospital Center
Lyon, France
Paoli-Calmettes Institute
Marseille, France
University Hospital of Nantes
Nantes, France
Hospital Center Universitaire De Nice
Nice, France
Saint-Louis Hospital
Paris, France
University Duisburg-Essen, University Hospital Essen, Department of Internal Medicine
Essen, Germany
University Hospital Hamburg-Eppendorf, Department of Internal Medicine II
Hamburg, Germany
Hannover Medical School, Center for Internal Medicine, Clinic of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation
Hanover, Germany
University Hospital Jena, Clinic of Internal Medicine II, Department of Hematology and Medical Oncology
Jena, Germany
University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology
Halle, Saxony-Anhalt, Germany
University Hospital - Ospedali Riuniti Umberto I - GM Lancisi - G Salesi of Ancona, Haematology Clinic
Ancona, Italy
Polyclinic S. Orsola-Malpighi, Operative Unit of Hematology
Bologna, Italy
Romagnolo Scientific Institute of Meldola (IRST) S.r.l., Department of Oncology and Clinical and Experimental Haematology
Meldola, Italy
Gachon University Gil Medical Center
Incheon, South Korea
Seoul National University Hospital, Department of Hemato-Oncology
Seoul, South Korea
University Hospital Germans Trias i Pujol, Department of Clinical Hematology
Badalona, Spain
University Hospital Vall d'Hebron
Barcelona, Spain
University Clinical Hospital of Valencia, Department of Hematology and Medical Oncology
Valencia, Spain
Hospital Universitario y Politécnico de La Fe
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.